Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2006

View Archived Issues

Aerosolized hydroxychloroquine studied in phase II for asthma

Bayer concludes divestment of antiinfectives research to Santo Holding

Orphan drug designation for SLIT Amikacin

American businesses of Sankyo and Daiichi to integrate

Immtech International changes name to Immtech Pharmaceuticals

Vertex and CFFT form new collaboration to develop VX-770 for cystic fibrosis

Samaritan concluding preclinical studies of SP-233 for Alzheimer's disease

Allergan completes acquisition of Inamed

Enrollment completed in phase III study of TH-9507 for HIV lipodystrophy

Phase III hepatorenal syndrome study of terlipressin completes enrollment

Schering AG supports Bayer offer

FDA Advisory Committee recommends against approval of Sparlon for ADHD

TBC-3711 on clinical hold following rat finding

Phase I/II study evaluates nimotuzumab for NSCLC

Idenix modifies phase IIb trials of valopicitabine

Phase II findings for ACP-103 for treatment-induced psychosis in Parkinson's

Orphan drug designation for Aastrom's Tissue Repair Cells in osteonecrosis

Spectrum to acquire oncology drug assets of Targent

Ranexa now available for chronic angina

Approvable letter for Thelin in PAH

In vivo efficacy of a novel CCR3 antagonist for allergic inflammatory disease

Avidex reports new immunomodulatory agents

Recent patents report new therapeutic agents for metabolic disorders

BMS-355249: novel potentiator of NT-3-mediated trk A and trk B activation

Novel LFA-1 antagonist demonstrates biological activity in vivo

Dipyridamole analogue potently inhibits ENT1

Spotlight on prostaglandin E2 EP1 receptors as mediators of neurotoxicity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...